Oncotelic Therapeutics, Inc. (OTLC): Entry into a Material Definitive Agreement
Oncotelic Therapeutics, Inc. (OTLC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 23, 2026, by and between ONCOTELIC THERAPEUTICS, INC. , a Delaware corporation, with headquarters located at 29397 Agoura Road Suite 107,
How this was made
The 30-second read
Why it matters
This is a capital-raise event that introduces an equity-linked overhang; dilution risk depends on the Note’s conversion terms, which are not included in the provided excerpt.
Market read
Convertible note financings often trigger sell-the-news behavior and elevated volatility as traders model dilution and conversion scenarios.
What to watch
Traders should focus on the missing Note conversion mechanics (conversion price, discount, caps, maturity, and any default provisions) and whether the 500,000 commitment shares are immediately tradable or subject to restrictions.
Background
The 8-K reports entry into a material definitive securities purchase agreement, including issuance of a convertible promissory note and additional common shares as consideration.
Ticker impact
Oncotelic Therapeutics entered a securities purchase agreement issuing a $178,410 convertible promissory note plus 500,000 commitment shares to Pacific Pier Capital II.
Near-term downside bias is plausible due to dilution/financing overhang, with volatility around conversion terms and any subsequent share issuance.
The 8-K is a primary-source disclosure of a new note and commitment shares; however, the excerpt does not include conversion price/terms, so magnitude of dilution and immediate valuation impact can’t be fully quantified.
Market effects
Microcap biotech financing via convertible notes can reinforce a broader risk premium for similar capital-constrained issuers.
Limited; primarily affects the US microcap/OTC liquidity pocket for the issuer.
Low; deal size is small and not systemically relevant.
Counterpoint
If the note’s conversion terms are favorable (e.g., high conversion price or capped dilution), the financing could be less dilutive than feared and may extend runway without immediate equity selling pressure.
Key entities
- issuerOncotelic Therapeutics, Inc.
Company filing the 8-K and issuing the convertible promissory note and commitment shares.
- buyerPacific Pier Capital II, LP
Investor purchasing the note and receiving 500,000 commitment shares as additional consideration.
